Randomized trial: Inhaled Treprostinil in pulmonary hypertension due to interstitial lung disease
17 Jan, 2021 | 21:47h | UTCCommentaries: Inhaled Treprostinil Beneficial in Pulmonary Hypertension – HealthDay
Commentary on Twitter
Patients with pulmonary hypertension due to interstitial lung disease were randomly assigned to inhale treprostinil or placebo. At 16 weeks, there was a significant improvement in exercise capacity with inhaled treprostinil as compared with placebo, assessed by a 6-minute walk.
— NEJM (@NEJM) January 14, 2021